Lindsay McNair | Profiles RNS

Lindsay A McNair, MD, MPH

Adjunct Assistant Professor

Boston University School of Public Health

Epidemiology

MD, University of Connecticut
MPH, Boston University
BS, Trinity College

Websites

	WCG
	LinkedIn
	School of Public Health Faculty

ORCID : 0000-0003-2458-8550

Lindsay McNair, MD, MPH, MSBioethics is the Chief Medical Officer for the WIRB-Copernicus Group (WCG). Dr. McNair has extensive experience in the pharmaceutical industry working in clinical research and drug development. Prior to joining WCG, she was a consultant to pharmaceutical and biotechnology companies, providing medical guidance on clinical development strategies and study designs for new drug studies, and medical oversight of all phases of clinical trials. Dr. McNair is adjunct faculty at Boston University and teaches graduate-level courses on the scientific design of clinical research studies, research ethics and the responsible conduct of research, and the development of clinical study protocols. She now oversees the physician team within the WCG IRBs, and provides consultation to institutions and pharma/biotech companies on a wide range of issues related to protocol design, regulatory compliance, human subject protection, and ethical policy development (compassionate use, etc).

Dr. McNair graduated from the University of Connecticut School of Medicine and trained in general surgery at Boston University Medical Center. She completed her Master’s in Public Health at Boston University concentrating in Biostatistics/Epidemiology, and her Master’s of Science in Bioethics at Union Graduate College concentrating in research ethics. She was a member of the Institutional Review Board at Boston University Medical Center, and founded and chaired the Human Subject Protection Committee at Vertex Pharmaceuticals. She was a site visitor for the Association of the Accreditation of Human Research Protection Programs (AAHRPP). Dr. McNair serves on committees including the Multi-Regional Clinical Trials Center at Harvard, and is an associate editor of the Journal of Empirical Research on Human Research Ethics.

BU Research
BMC Research

Lymphedema in Survivors of Early Breast Cancer
10/01/1999 - 03/31/2004 (PI)
Susan G. Komen Breast Cancer Foundation

Lymphedema In Survivors Of Ear
01/01/1999 - 09/30/2002 (PI)
DPH

Lymphedema In Survivors Of Ebc
10/01/1999 - 01/16/2000 (PI)
Susan G. Komen for the Cure

Title

Yr	Title	Project-Sub Proj	Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis Copy PMIDs To Clipboard

Hart PA, Andersen DK, Lyons E, Cote GA, Cruz-Monserrate Z, Dworkin RH, Elmunzer BJ, Fogel EL, Forsmark CE, Gilron I, Golden M, Gozu A, McNair L, Pandol SJ, Perito ER, Phillips AE, Rabbitts JA, Whitcomb DC, Windsor JA, Yadav D, Palermo TM. Clinical Trials in Pancreatitis: Opportunities and Challenges in the Design and Conduct of Patient-Focused Clinical Trials in Recurrent Acute and Chronic Pancreatitis: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop. Pancreas. 2022 Aug 01; 51(7):715-722. PMID: 36395394; PMCID: PMC9697224; DOI: 10.1097/MPA.0000000000002105;

McNair L. Ethical and regulatory oversight of clinical research: The role of the Institutional Review Board. Exp Biol Med (Maywood). 2022 Apr; 247(7):561-566. PMID: 35172623; PMCID: PMC9014527; DOI: 10.1177/15353702221078216;

Cooper JA, McNair L. Authors' Response to "Comment on the Proposed Institutional Review Board Retrospective Review of Research". J Empir Res Hum Res Ethics. 2020 07; 15(3):232. PMID: 32102599

Cooper JA, McNair L. Retrospective Review of Research. J Empir Res Hum Res Ethics. 2020 07; 15(3):227-228. PMID: 31808710

McNair L. Keeping a Focus on Research Ethics. Ther Innov Regul Sci. 2018 05; 52(3):267. PMID: 29723061; DOI: 10.1177/2168479018769293;

Anderson E, McNair L. Ethical Issues in Research Involving Participants With Opioid Use Disorder. Ther Innov Regul Sci. 2018 05; 52(3):280-284. PMID: 29714588; PMCID: PMC5944085; DOI: 10.1177/2168479018771682;

Li RH, Wacholtz MC, Barnes M, Boggs L, Callery-D'Amico S, Davis A, Digilova A, Forster D, Heffernan K, Luthin M, Lynch HF, McNair L, Miller JE, Murphy J, Van Campen L, Wilenzick M, Wolf D, Woolston C, Aldinger C, Bierer BE. Incorporating ethical principles into clinical research protocols: a tool for protocol writers and ethics committees. J Med Ethics. 2016 Apr; 42(4):229-34. PMID: 26811365; PMCID: PMC4819642; DOI: 10.1136/medethics-2014-102540;

McNair LA, Biffl WL. Assessing Awareness and Implementation of a Recommendation for Surgical Innovation Committees: A Survey of Academic Institutions. Ann Surg. 2015 Dec; 262(6):941-8. PMID: 25373465; DOI: 10.1097/SLA.0000000000001037;

Cooper JA, McNair L. Sham Surgery Research. J Empir Res Hum Res Ethics. 2015 Dec; 10(5):496-8. PMID: 26564946; DOI: 10.1177/1556264615614942;

Cooper JA, McNair L. How to distinguish research from quality improvement. J Empir Res Hum Res Ethics. 2015 Apr; 10(2):209-10. PMID: 25819760; DOI: 10.1177/1556264615575513;

Showing 10 of 30 results. Show More

Cooper JA, McNair L. Simplifying the complexity of confidentiality in research. J Empir Res Hum Res Ethics. 2015 Feb; 10(1):100-2. PMID: 25742671; DOI: 10.1177/1556264614568783;

Cooper JA, McNair L. What Is the Role of a Statistician on the IRB? J Empir Res Hum Res Ethics. 2014 Dec; 9(5):89-90. PMID: 25747693; DOI: 10.1177/1556264614554899;

Cooper JA, McNair L. IRB Authority. J Empir Res Hum Res Ethics. 2014 Oct; 9(4):86-7. PMID: 25747299; DOI: 10.1177/1556264614548836;

Curry MP, Forns X, Chung RT, Terrault NA, Brown R, Fenkel JM, Gordon F, O'Leary J, Kuo A, Schiano T, Everson G, Schiff E, Befeler A, Gane E, Saab S, McHutchison JG, Subramanian GM, Symonds WT, Denning J, McNair L, Arterburn S, Svarovskaia E, Moonka D, Afdhal N. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology. 2015 Jan; 148(1):100-107.e1.View Related Profiles.

Gordon, Fredric
McNair, Lindsay

PMID: 25261839; DOI: 10.1053/j.gastro.2014.09.023;

Cooper JA, McNair L. Scientific review by the ethics committee. J Empir Res Hum Res Ethics. 2014 Jul; 9(3):93-4. PMID: 25746791; DOI: 10.1177/1556264614540590;

Garg V, Chandorkar G, Yang Y, Adda N, McNair L, Alves K, Smith F, van Heeswijk RP. The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers. Br J Clin Pharmacol. 2013 Feb; 75(2):431-9. PMID: 22642697; PMCID: PMC3579258; DOI: 10.1111/j.1365-2125.2012.04345.x;

Glickman SW, Galhenage S, McNair L, Barber Z, Patel K, Schulman KA, McHutchison JG. The potential influence of Internet-based social networking on the conduct of clinical research studies. J Empir Res Hum Res Ethics. 2012 Feb; 7(1):71-80. PMID: 22378136; DOI: 10.1525/jer.2012.7.1.71;

Kablinger AS, Lindner MA, Casso S, Hefti F, DeMuth G, Fox BS, McNair LA, McCarthy BG, Goeders NE. Effects of the combination of metyrapone and oxazepam on cocaine craving and cocaine taking: a double-blind, randomized, placebo-controlled pilot study. J Psychopharmacol. 2012 Jul; 26(7):973-81. PMID: 22236504; DOI: 10.1177/0269881111430745;

Rustgi VK, Lee WM, Lawitz E, Gordon SC, Afdhal N, Poordad F, Bonkovsky HL, Bengtsson L, Chandorkar G, Harding M, McNair L, Aalyson M, Alam J, Kauffman R, Gharakhanian S, McHutchison JG. Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders. Hepatology. 2009 Dec; 50(6):1719-26. PMID: 19852040; DOI: 10.1002/hep.23204;

McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, Alam J, Muir AJ. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009 Apr 30; 360(18):1827-38. PMID: 19403902; DOI: 10.1056/NEJMoa0806104;

Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, Bourlière M, Gharakhanian S, Bengtsson L, McNair L, George S, Kieffer T, Kwong A, Kauffman RS, Alam J, Pawlotsky JM, Zeuzem S. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009 Apr 30; 360(18):1839-50. PMID: 19403903; DOI: 10.1056/NEJMoa0807650;

Kwong AD, McNair L, Jacobson I, George S. Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors. Curr Opin Pharmacol. 2008 Oct; 8(5):522-31. PMID: 18835365; DOI: 10.1016/j.coph.2008.09.007;

Lawitz E, Rodriguez-Torres M, Muir AJ, Kieffer TL, McNair L, Khunvichai A, McHutchison JG. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J Hepatol. 2008 Aug; 49(2):163-9. PMID: 18486984; DOI: 10.1016/j.jhep.2008.03.027;

Gelderblom HC, Zeuzem S, Weegink CJ, Forestier N, Mcnair L, Purdy S, Dijkgraaf MG, Jansen PL, Reesink HW. Inflammatory markers neopterin and alanine aminotransferase in HCV patients treated with HCV NS3.4A protease inhibitor telaprevir (VX-950) and/or peginterferon alfa-2a. Scand J Gastroenterol. 2008; 43(9):1122-7. PMID: 18609142; DOI: 10.1080/00365520802044210;

Forestier N, Reesink HW, Weegink CJ, McNair L, Kieffer TL, Chu HM, Purdy S, Jansen PL, Zeuzem S. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology. 2007 Sep; 46(3):640-8. PMID: 17879366

Marcellin P, Horsmans Y, Nevens F, Grange JD, Bronowicki JP, Vetter D, Purdy S, Garg V, Bengtsson L, McNair L, Alam J. Phase 2 study of the combination of merimepodib with peginterferon-alpha2b, and ribavirin in nonresponders to previous therapy for chronic hepatitis C. J Hepatol. 2007 Oct; 47(4):476-83. PMID: 17629590

Reesink HW, Zeuzem S, Weegink CJ, Forestier N, van Vliet A, van de Wetering de Rooij J, McNair L, Purdy S, Kauffman R, Alam J, Jansen PL. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology. 2006 Oct; 131(4):997-1002. PMID: 17030169

McHutchison JG, Shiffman ML, Cheung RC, Gordon SC, Wright TL, Pottage JC, McNair L, Ette E, Moseley S, Alam J. A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C. Antivir Ther. 2005; 10(5):635-43. PMID: 16152757

Beaulac SM, McNair LA, Scott TE, LaMorte WW, Kavanah MT. Lymphedema and quality of life in survivors of early-stage breast cancer. Arch Surg. 2002 Nov; 137(11):1253-7.View Related Profiles.

McNair, Lindsay
Kavanah, Maureen
Scott, Thayer
LaMorte, Wayne

PMID: 12413312

Nagler-Anderson C, McNair LA, Cradock A. Self-reactive, T cell receptor-gamma delta+, lymphocytes from the intestinal epithelium of weanling mice. J Immunol. 1992 Oct 1; 149(7):2315-22. PMID: 1382095

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 30 publications over 16 distinct years, with a maximum of 4 publications in 2014 and 2015

Bar chart showing 30 publications over 16 distinct years, with a maximum of 4 publications in 2014 and 2015

Year	Publications
1992	1
2002	1
2005	1
2006	1
2007	2
2008	3
2009	3
2012	2
2013	1
2014	4
2015	4
2016	1
2018	2
2019	1
2020	1
2022	2

Contact for Mentoring:

72 E. Concord St Instructional (L)
Boston MA 02118
Google Map

617.358.3728

Download vCard

McNair's Networks

Click the "See All" links for more information and interactive visualizations

Concepts

See all (151) concept(s)

Co-Authors

See all (2) people

Similar People

See all (60) people

Same Department

Search Department